KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash from Financing Activities (2016 - 2025)

Quest Diagnostics' Cash from Financing Activities history spans 17 years, with the latest figure at -$287.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 68.82% year-over-year to -$287.0 million; the TTM value through Dec 2025 reached -$1.4 billion, down 228.04%, while the annual FY2025 figure was -$1.4 billion, 228.04% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$287.0 million at Quest Diagnostics, down from -$247.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.8 billion in Q3 2024 and bottomed at -$1.6 billion in Q2 2021.
  • The 5-year median for Cash from Financing Activities is -$267.0 million (2025), against an average of -$220.8 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 1147.37% in 2022 before it soared 2232.53% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$369.0 million in 2021, then tumbled by 47.7% to -$545.0 million in 2022, then surged by 123.85% to $130.0 million in 2023, then crashed by 230.77% to -$170.0 million in 2024, then crashed by 68.82% to -$287.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Cash from Financing Activities are -$287.0 million (Q4 2025), -$247.0 million (Q3 2025), and -$293.0 million (Q2 2025).